TY - JOUR
T1 - A placebo-controlled study examining the effect of allopurinol on heart rate variability and dysrhythmia counts in chronic heart failure
AU - Shehab, Abdullah M.A.
AU - Butler, Robert
AU - MacFadyen, Robert J.
AU - Struthers, Allan D.
PY - 2001
Y1 - 2001
N2 - Aims: Allopurinol improves endothelial function in chronic heart failure by reducing oxidative stress. We wished to explore if such an effect would attenuate autonomic dysfunction in CHF in line with many other effective therapies in CHF. Methods: We performed a prospective, randomized, double-blind cross-over study in 16 patients with NYHA Class II-IV chronic heart failure (mean age 67 ± 10 years, 13 male, comparing allopurinol (2 months) at a daily dose of 300 mg (if creatinine < 150 μmol l -1) or 100 mg (if creatinine > 150 μmol l -1) with matched placebo. Mean heart rate and dysrhythmia counts were recorded from 24 h Holter tapes at monthly intervals for 6 months. We assessed autonomic function using standard time domain heart rate variability parameters (HRV): SDNN, SDANN, SDNN index, rMSSD and TI. Results: Allopurinol had no significant effect on heart rate variability compared with placebo; the results are expressed as a difference in means ± s.d. with 95% confidence interval (CI) between allopurinol and placebo: SDNN mean = 6.5 ± 4.8 ms, P = 0.18 and 95% CI (-3.7, 17); TI mean = -2.1 ± 1.4, P = 0.16 and 95% CI (-5.2, 0.8); SDANN mean = -2.8 ± 7 ms, P = 0.68 and 95% CI (-18, 12); SDNNi mean = 2 ± 6.6, P = 0.7 and 95% CI (-12, 16); RMSSD mean = -0.9 ± 2, P = 0.68 and 95% CI (-5.6, 3.7). For mean heart rate the corresponding results were 0.9 ± 1.4, P = 0.5 and 95% CI (-2, 3.8). Log 24 h ventricular ectopic counts (VEC) were 0.032 ± 0.37, P = 0.7 and 95% CI (-0.1, 0.2). Patient compliance with study medication was good since allopurinol showed its expected effect of reducing plasma uric acid (P < 0.001). Conclusions: Allopurinol at doses, which are known to reduce oxidative stress appear to have no significant effect on resting autonomic tone, as indicated by time domain heart rate variability or on dysrhythmia count in stable heart failure patients.
AB - Aims: Allopurinol improves endothelial function in chronic heart failure by reducing oxidative stress. We wished to explore if such an effect would attenuate autonomic dysfunction in CHF in line with many other effective therapies in CHF. Methods: We performed a prospective, randomized, double-blind cross-over study in 16 patients with NYHA Class II-IV chronic heart failure (mean age 67 ± 10 years, 13 male, comparing allopurinol (2 months) at a daily dose of 300 mg (if creatinine < 150 μmol l -1) or 100 mg (if creatinine > 150 μmol l -1) with matched placebo. Mean heart rate and dysrhythmia counts were recorded from 24 h Holter tapes at monthly intervals for 6 months. We assessed autonomic function using standard time domain heart rate variability parameters (HRV): SDNN, SDANN, SDNN index, rMSSD and TI. Results: Allopurinol had no significant effect on heart rate variability compared with placebo; the results are expressed as a difference in means ± s.d. with 95% confidence interval (CI) between allopurinol and placebo: SDNN mean = 6.5 ± 4.8 ms, P = 0.18 and 95% CI (-3.7, 17); TI mean = -2.1 ± 1.4, P = 0.16 and 95% CI (-5.2, 0.8); SDANN mean = -2.8 ± 7 ms, P = 0.68 and 95% CI (-18, 12); SDNNi mean = 2 ± 6.6, P = 0.7 and 95% CI (-12, 16); RMSSD mean = -0.9 ± 2, P = 0.68 and 95% CI (-5.6, 3.7). For mean heart rate the corresponding results were 0.9 ± 1.4, P = 0.5 and 95% CI (-2, 3.8). Log 24 h ventricular ectopic counts (VEC) were 0.032 ± 0.37, P = 0.7 and 95% CI (-0.1, 0.2). Patient compliance with study medication was good since allopurinol showed its expected effect of reducing plasma uric acid (P < 0.001). Conclusions: Allopurinol at doses, which are known to reduce oxidative stress appear to have no significant effect on resting autonomic tone, as indicated by time domain heart rate variability or on dysrhythmia count in stable heart failure patients.
KW - Allopurinol
KW - Dysrhythmia
KW - Heart failure
KW - Heart rate variability
KW - Ischaemic stress
KW - Mean heart rate
KW - Mortality
KW - NO
KW - Oxidant stress
KW - Uric acid
UR - http://www.scopus.com/inward/record.url?scp=0035035605&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035035605&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2125.2001.01361.x
DO - 10.1046/j.1365-2125.2001.01361.x
M3 - Article
C2 - 11318768
AN - SCOPUS:0035035605
SN - 0306-5251
VL - 51
SP - 329
EP - 334
JO - British Journal of Clinical Pharmacology
JF - British Journal of Clinical Pharmacology
IS - 4
ER -